| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Heyman Richard A. is a Director at Oric Pharmaceuticals, Inc. with holdings across 3 companies. Recent SEC Form 4 filings include 0 buys and 20 sells.
Estimated insider holdings value: $2.9M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 1,270 | $21.48 | $27,277.95 | -0.9% | +3.8% | +1.1% | |
| May 16, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 1,270 | $23.74 | $30,149.67 | -0.9% | -8.4% | -29.2% | |
| Apr 15, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 6,964 | $24.11 | $167,887.52 | -2.2% | +25.9% | -14.5% | |
| Mar 19, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 1,270 | $14.50 | $18,418.68 | -0.9% | +22.9% | +19.1% | |
| Feb 15, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 1,270 | $17.42 | $22,117.43 | -0.9% | +38.7% | +25.3% | |
| Jan 30, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 1,270 | $16.41 | $20,839.56 | -0.9% | +9.3% | +28.1% | |
| Dec 22, 2023 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 216 | $13.00 | $2,808.00 | - | +21.6% | +51.3% | |
| Dec 20, 2023 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 4,280 | $13.02 | $55,727.05 | -1.3% | +43.9% | +87.6% | |
| Sep 15, 2021 | ORIC Oric Pharmaceuticals, Inc. | Director | Sell | 1,388 | $25.04 | $34,759.74 | -0.3% | -52.1% | -86.6% | |
| Sep 13, 2021 | ORIC Oric Pharmaceuticals, Inc. | Director | Sell | 1,080 | $25.05 | $27,056.13 | -0.2% | -47.5% | -86.1% |